Deferasirox

Introduction Overview

Generic Name

deferasirox

Brand Name

Jadenu

Dosage Form

oral tablet, oral sprinkle formulation

Drug Class

Chelating agents

Pharmacokinetics

Absorption:
Deferasirox exhibits rapid and extensive absorption following oral administration, with peak plasma concentrations typically reached within 1.5 to 4 hours. The oral bioavailability is generally high, facilitating effective systemic exposure. It is recommended to take Jadenu on an empty stomach or with a light, low-fat meal to optimize absorption and reduce gastrointestinal intolerance. Food, especially high-fat meals, can slightly reduce the rate but does not significantly affect total systemic exposure. The sprinkle formulation enhances patient compliance, especially in pediatric populations unable to swallow tablets.

Distribution:
After systemic absorption, deferasirox is highly protein bound (>99%), predominantly to albumin, which limits the free drug fraction but prolongs systemic circulation. The volume of distribution approximates total body water, indicating distribution into extracellular fluids. Distribution to various tissues is essential to chelate excess intracellular and extracellular iron, particularly in organs vulnerable to iron overload such as the liver, heart, and endocrine glands. The high plasma protein binding also impacts drug interactions and elimination profile.

Metabolism:
Deferasirox undergoes hepatic metabolism primarily via glucuronidation mediated by uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, with minor contributions from cytochrome P450 isoenzymes. The principal metabolites are pharmacologically inactive, facilitating safe clearance. The metabolism is saturable at high doses, necessitating careful dose titration and monitoring to prevent toxicity. Hepatic impairment may alter metabolic capacity, increasing drug exposure and risk of adverse effects.

Elimination:
The elimination half-life of deferasirox ranges between 8 to 16 hours, allowing once-daily dosing regimens. Excretion occurs mainly via feces (approximately 80%), with biliary secretion of the glucuronide conjugates being the primary route. Renal excretion of unchanged drug is minimal (<10%), but renal function is critical to monitor given the drug's potential nephrotoxicity. Patients with severe renal impairment require dose adjustments or alternative therapies. The elimination kinetics support steady-state concentrations within 7 days of therapy initiation, guiding clinical monitoring strategies.

Dosage Forms

Available Dosage Forms:
- Oral tablet: Delayed-release (Jadenu tablets are film-coated, designed for once daily oral administration).
- Sprinkles: Oral sprinkle packets containing granules for mixing with soft food to facilitate administration, especially in pediatric or dysphagic patients.

Dosages for Adults and Adolescents:
- Initial dosing typically starts at 14 mg/kg once daily for transfusional iron overload patients.
- Dose adjustments are made based on serum ferritin levels, efficacy, and tolerability, with a therapeutic dose range from 7 mg/kg to 28 mg/kg daily.
- Administration should occur at the same time each day, with or without food, but consistency is encouraged.

Specific Patient Populations:
- Pediatric patients aged 2 years and above can safely receive therapy using the sprinkle formulation or tablets depending on swallowing ability.
- Patients with hepatic or renal impairment require careful dose titration and monitoring due to altered pharmacokinetics and increased risk of toxicity.
- Geriatric patients should be monitored closely owing to increased susceptibility to adverse effects.
- Dose modifications are necessary for patients with intermediate or advanced liver or kidney disease.

Clinical Guidelines and Administration:
- Tablets should be swallowed whole with water; if swallowing is difficult, tablets may be crushed and mixed immediately with yogurt or applesauce and consumed promptly without chewing.
- Sprinkles must be mixed with a spoonful of soft food and swallowed immediately; not to be stored after preparation.
- Frequent monitoring of kidney and liver function tests is recommended at baseline and periodically during therapy (minimum every six months).
- Regular blood testing including serum ferritin guides therapy efficacy and safety adjustments.

Mechanism Of Action

Deferasirox, the active component in Jadenu, functions as a selective oral iron chelator. Its primary molecular mechanism entails binding free iron (Fe3+) ions in the bloodstream with high affinity, forming a stable complex that reduces the labile plasma iron pool responsible for tissue deposition and oxidative damage. This complex is then excreted primarily via the hepatobiliary route, decreasing total body iron load.

At the cellular level, deferasirox efficiently chelates intracellular and extracellular iron, preventing the generation of harmful reactive oxygen species through Fenton chemistry. By lowering free iron availability, it reduces oxidative stress-mediated cellular injury in organs prone to iron overload, including the liver, heart, and endocrine tissues. This mechanism underlies its clinical utility in managing chronic iron overload due to repeated transfusions or ineffective erythropoiesis.

Biochemically, deferasirox forms a 2:1 complex with Fe3+ ions through nitrogen and oxygen donor atoms in its tridentate ligand structure. This stoichiometry ensures effective iron binding with high specificity, minimizing interaction with other metal ions. Comparative studies show deferasirox offers advantages over parenteral chelators like deferoxamine regarding patient compliance and oral bioavailability, while maintaining potent iron binding capacity.

Clinical studies demonstrate that regular administration of deferasirox reduces serum ferritin and liver iron concentration sustainably, correlating with decreased morbidity from iron overload complications. Additionally, ongoing research explores deferasirox’s potential antioxidant benefits and effects on cellular iron regulatory mechanisms, expanding its therapeutic implications beyond simple iron chelation.

Pharmacological Actions

Oral iron chelation through selective binding of ferric ions.
Reduction of systemic and tissue iron overload in transfusion-dependent anemias.
Formation of a stable iron-deferasirox complex excreted primarily via feces.
Decreases labile plasma iron, preventing oxidative tissue damage.
Improves survival and reduces organ damage in chronic iron overload patients.
Reduces hepatic iron concentration and serum ferritin levels effectively.
Exhibits high oral bioavailability supporting once-daily dosing.
Maintains a high plasma protein binding minimizing free active drug.
Metabolized via glucuronidation enhancing pharmacokinetic profile.
Minimal renal excretion limits nephrotoxicity compared to other chelators.
Demonstrates efficacy in both transfusion-dependent and non-transfusion-dependent thalassemia.
Aids in preserving cardiac function by reducing myocardial iron deposits.
Exhibits dose-dependent pharmacodynamics with manageable side effect profile.
Compatible with pediatric populations using sprinkle formulations.

Therapeutic Or Clinical Uses

Treatment of chronic iron overload due to repeated blood transfusions in patients aged 2 years and older.
Management of non-transfusion-dependent thalassemia with elevated body iron levels in patients aged 10 years and older.
Reduction of hepatic and systemic iron burden to prevent organ damage.
Alternative to parenteral iron chelation therapy for improved patient compliance.
Adjunct therapy in thalassemia major and other chronic anemias requiring lifelong transfusions.
Prevention of iron-mediated cardiac toxicity in patients with iron overload.
Used in patients with various hematologic disorders causing secondary iron overload.
Supportive therapy to maintain iron balance during long-term transfusion regimens.
Treatment of iron accumulation in sickle cell disease patients undergoing chronic transfusions.
May be considered in patients intolerant to other oral chelation agents.
Clinical indication extends to patients with myelodysplastic syndromes with iron overload.
Facilitates improvement in overall prognosis by attenuating iron-related complications.
Off-label use in investigational protocols for iron-loading anemias.

Side Or Adverse Effects

Gastrointestinal disturbances including nausea, vomiting, abdominal pain, and diarrhea.
Skin rash including mild erythematous eruptions and pruritus.
Kidney toxicity manifesting as elevated creatinine, reduced urine output, edema, and fatigue.
Liver dysfunction evidenced by elevated liver enzymes, jaundice, and hepatomegaly.
Low blood cell counts leading to anemia, thrombocytopenia, neutropenia, and increased infection risk.
Serious allergic reactions including urticaria, angioedema, and anaphylaxis.
Severe cutaneous adverse reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
Gastrointestinal bleeding presenting as bloody or tarry stools, hematemesis with coffee ground appearance.
Visual and auditory disturbances including blurred vision and hearing impairment.
Increased susceptibility to infections due to immune modulation.
Headache and dizziness possibly related to systemic iron depletion.
Fatigue and malaise secondary to systemic effects.
Potential increases in serum creatinine warranting monitoring and possible discontinuation.
Rare cases of hepatic failure and renal failure reported in predisposed patients.
Injection site reactions are not applicable given oral formulation but gastrointestinal intolerance is common.

Precautions

Baseline and periodic assessment of kidney and liver function is mandatory.
Use cautiously in patients with pre-existing renal or hepatic impairment.
Avoid use in patients with known hypersensitivity to deferasirox or components of Jadenu.
Screen for thrombocytopenia and bone marrow suppression before and during therapy.
Inform patients of symptoms indicative of organ toxicity such as jaundice, dark urine, or swelling.
Monitor blood counts regularly to detect early hematologic adverse effects.
Avoid co-administration with other iron-chelating agents unless clinically justified.
Consider dose adjustment or discontinuation with signs of severe adverse reactions.
Use effective non-hormonal contraception during treatment as Jadenu may reduce hormonal contraceptive efficacy.
Not recommended during pregnancy unless potential benefits outweigh risks; avoid breastfeeding during treatment.
Patients with active gastrointestinal ulcers or bleeding require careful evaluation before starting therapy.
Advise patients to report visual or auditory symptoms promptly.
Dose modifications recommended in elderly patients due to increased side effect risk.
Consider drug interaction potential with concomitant medications including antacids and nephrotoxic agents.
Educate patients on proper administration techniques, especially relating to sprinkle formulations.

Warnings

Contraindicated in patients with severe kidney disease or renal failure.
Avoid use in severe liver disease or advanced hepatic impairment.
Not to be used in patients with advanced cancers or hematologic malignancies affecting bone marrow.
Contraindicated in patients with low platelet counts or bone marrow disorders due to risk of bleeding.
Potential hepatotoxicity requiring vigilance for symptoms such as abdominal pain, jaundice, and dark urine.
Risk of severe renal impairment warrants close monitoring of renal parameters.
Serious skin reactions including Stevens-Johnson syndrome necessitate immediate discontinuation.
Stomach or intestinal bleeding is a serious risk; emergent evaluation required if gastrointestinal hemorrhage occurs.
Jadenu may reduce the effectiveness of hormonal contraceptives leading to unintended pregnancy.
Use with caution in immunocompromised patients due to increased risk of infection.
May impair cognitive and motor functions; caution advised when performing tasks requiring alertness.
Not established as safe or effective in combination with other iron chelators without supervision.
Discontinue if signs of hypersensitivity or severe allergic reactions occur.
Requires adjustment or discontinuation upon evidence of substantial hematologic toxicity.
Use in pregnancy only if the potential benefit justifies the potential risk to fetus.

Contraindication

Known allergy or hypersensitivity to deferasirox or any component of Jadenu.
Severe renal impairment or renal failure.
Severe hepatic impairment or active liver disease.
Advanced hematologic cancers or bone marrow disorders.
Thrombocytopenia or abnormally low platelet counts.
Active gastrointestinal bleeding or peptic ulcer disease with bleeding symptoms.
Concomitant use of other iron chelators unless under specialized medical advice.
Pregnancy without compelling clinical indication and safety assurance.
Breastfeeding due to unknown excretion and effects on infant.
Use in patients with severe uncontrolled infections unless benefits outweigh risks.
Known cases of Stevens-Johnson syndrome or toxic epidermal necrolysis with prior therapy.
Patients unable to swallow tablets and not suitable for sprinkle formulation without supervision.
Concomitant use with medications that strongly inhibit UGT enzymes affecting metabolism.
Known hypersensitivity to film coating or excipients in the tablet formulation.
Patients with severe hypersensitivity reactions to previous deferasirox exposure.

Drug Interactions

Concurrent use with other iron-chelating agents such as deferoxamine contraindicated without medical supervision.
Antacids containing aluminum reduce deferasirox absorption; avoid concomitant administration.
Concomitant nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) increase risk of kidney toxicity.
Drugs metabolized by UGT enzymes may alter deferasirox metabolism leading to increased toxicity or reduced efficacy.
Potential interaction with warfarin requiring close INR monitoring due to altered coagulation parameters.
May reduce effectiveness of hormonal contraceptives, necessitating alternative birth control methods.
Co-administration with drugs causing bone marrow suppression may exacerbate hematologic adverse effects.
Herbal supplements and vitamins containing iron may counteract chelation effect.
Concomitant use with drugs that prolong QT interval should be cautious given potential additive effects.
Interaction with cyclosporine can increase nephrotoxic risk.
Concomitant use of drugs inducing glucuronidation may reduce deferasirox plasma levels.
Potential interaction with rifampin, phenytoin, or carbamazepine requires monitoring due to enzyme induction.
Avoid simultaneous use of aluminum-containing phosphate binders or laxatives.
Monitoring required when administered with hepatotoxic agents due to additive liver injury risk.
Careful therapeutic drug monitoring advised when up-titrating or down-titrating dosing due to drug interaction potential.

Preparations Of The Drug

Film-coated oral tablets available in strengths suitable for dosing based on mg/kg body weight.
Oral sprinkle granules packaged in single-dose packets for mixing with soft foods.
Tablets formulated for once-daily administration to improve adherence.
Sprinkle formulation designed for pediatric and adult patients with swallowing difficulties.
Manufactured to ensure minimal excipients that may cause hypersensitivity.
Packaged to protect from moisture and heat, preserving stability at room temperature.
Included patient information leaflets detailing administration and storage instructions.
Available under proprietary brand names Jadenu and Jadenu Sprinkle for clinical use.
Prepared under strict regulatory standards by approved pharmaceutical manufacturers.
Dosage strengths generally include increments that allow for fine dose titration (e.g., 90 mg, 180 mg, 360 mg tablets).
Formulations are bioequivalent to other deferasirox products but designed for improved palatability.
Packaged with comprehensive medication guides to indicate potential side effects and precautions.
Dispersible properties of sprinkle granules ensure rapid mixing and ease of ingestion.
Stable shelf life of at least 24 months when stored under recommended conditions.
No injectable or intravenous formulations currently available for deferasirox.